register free | resend password

Pressemitteilungen zu dem Thema tetra


Unterkategorien

PresseMitteilungen zu dem Schlagwort tetra


Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria

OTTAWA, ONTARIO -- (Marketwired) -- 11/16/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. ("Aphria") under Access to Cannabis for Medical Purposes Regulations (ACMPR).Based on the most recent A ...


16.11.2017

Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device

OTTAWA, ONTARIO -- (Marketwired) -- 11/09/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps™ inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps™."I am happy to announce the first batch order of our medical cannabis inhalation devices. This is the first step in g ...


09.11.2017

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

OTTAWA, ONTARIO -- (Marketwired) -- 10/26/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.Last year Tetra launched several drug development programs to commercialize c ...


26.10.2017

Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

OTTAWA, ONTARIO -- (Marketwired) -- 10/19/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).Dr. Jourdain will be responsible for the medical information of Rx Princeps™ and will be educating the medical community about the benefits of this controlled and standardized blend of m ...


19.10.2017

Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

OTTAWA, ONTARIO -- (Marketwired) -- 10/18/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princeps™, its unique blend of drie ...


18.10.2017

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

OTTAWA, ONTARIO -- (Marketwired) -- 10/13/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market - Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.Drs. Cullen and Webb hav ...


13.10.2017

Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18

OTTAWA, ONTARIO -- (Marketwired) -- 10/04/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel. Robert (Bob) Bechard, Vice-President, Finance and Business Development of Tetra will prese ...


04.10.2017

Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market

OTTAWA, ONTARIO -- (Marketwired) -- 09/28/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.AES Environment has expertise in in situ air testing analysis of all kinds of contaminants and development of high level air c ...


28.09.2017

Tetra Bio-Pharma to engage in co-development and distribution partnership with major healthcare specialty distributor

OTTAWA, ONTARIO -- (Marketwired) -- 09/20/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.This privately-owned partner, which asked to remain unnamed for the time being, has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have ac ...


20.09.2017

Tetra Bio-Pharma accelerates its clinical research program in the veterinary market by entering into agreement with Dr. Louis-Philippe de Lorimier

OTTAWA, ONTARIO -- (Marketwired) -- 09/11/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that it has added international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market."We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated sup ...


11.09.2017

Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference - BioPharm America

OTTAWA, ONTARIO -- (Marketwired) -- 09/07/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.BioPharm America is one of the premiere BioPartnering events providing ac ...


07.09.2017

Tetra Bio-Pharma Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities

OTTAWA, ONTARIO -- (Marketwired) -- 08/29/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF) today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017. Mr. ...


29.08.2017

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

OTTAWA, ONTARIO -- (Marketwired) -- 08/16/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). Tetra''s shares will commence trading on the TSX Venture on the opening of markets on Wedne ...


16.08.2017

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

OTTAWA, ONTARIO -- (Marketwired) -- 07/24/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Bo ...


24.07.2017

Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics

OTTAWA, ONTARIO -- (Marketwired) -- 07/19/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.The AgroTek Health subsidiary of Tetra will work with Constance ...


19.07.2017

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders'' Meeting & Provides a Corporate Update

OTTAWA, ONTARIO -- (Marketwired) -- 07/11/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders'' meeting.At the meeting, some key corporate highlights which were discussed, included:About Tetra Bio-Pharma:Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF) engaged in ...


11.07.2017

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals

OTTAWA, ONTARIO -- (Marketwired) -- 07/05/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytic ...


05.07.2017

Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market

OTTAWA, ONTARIO -- (Marketwired) -- 06/28/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.Over the last year, Tetra demonstrated its leadership in the development of human prescription cannabinoid drugs and will use the same strategy to become a leader in the field of veterinary cannabinoid drug pro ...


28.06.2017

Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors

OTTAWA, ONTARIO -- (Marketwired) -- 06/14/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF) today announced that it has appointed Mr. Carl A. Merton to the Board of Directors, effective immediately.Mr. Merton has over 20 years of financial and business experience, including 10 years experience as a CFO for public companies involved in the capital markets. Beginning with 12 years combined with Ernst & Young and KPMG, ...


14.06.2017

Tetra Bio-Pharma Announces UNB Cannabis Health Research Chair

OTTAWA, ONTARIO -- (Marketwired) -- 06/13/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF) and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB).The chair will focus on the study of biochemistry, medicinal use and pharmacology of cannabis. This research will expand UNB&# ...


13.06.2017

Tetra Bio-Pharma Announces the Completion of its Phase 1 Safety Report to Health Canada and Launches the Preparation of a Phase III Clinical Trial for PPP001 with Sante Cannabis

OTTAWA, ONTARIO -- (Marketwired) -- 06/07/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), and PhytoPain Pharma (PPP), a subsidiary of Tetra Bio-Pharma, is pleased to announce that it has submitted a report on the safety and pharmacokinetics of PPP001 (smokeable marijuana) to Health Canada. The Company is also launching the preparation of a Phase III clinical trial in collaboration with Quebec''s leading medi ...


07.06.2017

Tetra Bio-Pharma Strengthens Management Team

OTTAWA, ONTARIO -- (Marketwired) -- 05/10/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTCQB: GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.Mr. Bechard brings more than 20 years'' experience in the biopharmaceutical industry having worked for two lifescience venture capita ...


10.05.2017

Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales

OTTAWA, ONTARIO -- (Marketwired) -- 04/24/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP) (OTCQB: GRPOF), today announced that it has accelerated its sales strategy by entering into an employment agreement with Denis Courchesne as Vice President, Sales, effective Monday, May 1, 2017.Mr. Courchesne has over 25 years'' sales and management experience in the retail environment working for various companies such as Evian Spring Water (Danone) and Pfi ...


24.04.2017

Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec

OTTAWA, ONTARIO -- (Marketwired) -- 04/19/17 -- Tetra Bio-Pharma Inc. ("Tetra") (CSE: TBP)(CSE: TBP.CN)(OTCQB: GRPOF) and Aphria Inc. ("Aphria") (TSX: APH) (OTCQB: APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process d ...


19.04.2017

Tetra Bio-Pharma Upgrades to OTCQB to Engage and Expand U.S. Investor Audience

OTTAWA, ONTARIO -- (Marketwired) -- 04/05/17 -- Tetra Bio-Pharma Inc. ("Tetra") (CSE: TBP)(CSE: TBP.CN)(OTCQB: GRPOF), today announced that effective tomorrow, shares of the Company have been approved for and will commence trading on the OTCQB venture marketplace, operated by OTC Markets Group, under the ticker symbol GRPOF. Shares of the Company previously traded on the OTCQI Pink Sheet Market. The Company also reiterated its strategy to create greater opportunity for its shareholde ...


05.04.2017

Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications

OTTAWA, ONTARIO -- (Marketwired) -- 03/27/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), today announced that it entered into an employment agreement with Edward Miller as Vice President, Investor Relations and Corporate Communications effective today.Mr. Miller has over a decade of experience in the Biotech/Pharma industry. Most recently, he served as Director, Investor Relations and Corporate Communications at IntelGenx Co ...


27.03.2017

Aphria Exercises Warrants for Gross Proceeds of $1.3 Million to Further Fund Tetra''s Clinical Trials

OTTAWA, ONTARIO -- (Marketwired) -- 03/20/17 -- Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF) is pleased to announce that Aphria Inc. (TSX VENTURE: APH)(OTCQB: APHQF) has exercised their 5,000,000 warrants for aggregate gross proceeds of $1,300,000. The proceeds from the warrant exercise will be used to advance the clinical trials being developed in PhytoPain Pharma Inc., a subsidiary of Tetra."We would like to thank Aphr ...


20.03.2017

Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma

OTTAWA, ONTARIO -- (Marketwired) -- 03/14/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.Per the binding term sheet, Tetra ...


14.03.2017

Tetra Bio-Pharma Announces that the Delay in Legalization of Marijuana Does Not Affect its Drug Development & Commercialization Plans

OTTAWA, ONTARIO -- (Marketwired) -- 03/09/17 -- Tetra Bio-Pharma Inc. ("Tetra", "TBP" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), a biotechnology company specialized in the development and commercialization of Cannabis-based prescription drugs announced that the delay in legalization of marijuana does not affect its commercialization plans for 2017. AgroTek Health (AGT) for the over-the-counter self-care consumer markets is on schedule for the laun ...


09.03.2017

Tetra Bio-Pharma Grants Stock Options

OTTAWA, ONTARIO -- (Marketwired) -- 02/24/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF) announces that on February 23, 2017, in accordance with the Company''s stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 750,000 incentive stock options ("options") to its officers and directors of the Company. Each option, vesting immediat ...


24.02.2017

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)

OTTAWA, ONTARIO -- (Marketwired) -- 02/23/17 -- PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Asce ...


23.02.2017

UPDATE: Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

OTTAWA, ONTARIO -- (Marketwired) -- 02/16/17 -- PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.Tetra has worked w ...


16.02.2017

Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

OTTAWA, ONTARIO -- (Marketwired) -- 02/16/17 -- PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.Tetra has worked with Algorithme Ph ...


16.02.2017

TetraVue Secures $10M in Series A Funding to Bring Its 3D Technology to the Autonomous Car Industry

CARLSBAD, CA -- (Marketwired) -- 02/16/17 -- Providing advanced 3D technology, today announced the close of its Series A funding at $10M. The financing is led by Robert Bosch Venture Capital and Nautilus Venture Partners, and joined by Samsung Catalyst Fund as well as Foxconn. The funding will enable TetraVue to bring its Ultra High Definition, Solid State Flash LIDAR to the autonomous car industry, and to be the leader in Vision for Things (VfT)."We are thrilled to share that TetraVue ha ...


16.02.2017

Tetra Bio-Pharma and IntelGenx Announce the Signing of a Term Sheet for the Development and Commercialization of a Dronabinol XL Tablet

OTTAWA, ONTARIO -- (Marketwired) -- 02/09/17 -- Tetra Bio-Pharma Inc. ("Tetra") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF) and IntelGenx Corp. ("IntelGenx"), (TSX VENTURE: IGX)(OTCQX: IGXT), today announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the binding term sheet, Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the U.S. ...


09.02.2017

Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product

OTTAWA, ONTARIO -- (Marketwired) -- 02/01/17 -- PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for Phyt ...


01.02.2017

Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with Food and Drug Administration on PPP001

OTTAWA, ONTARIO -- (Marketwired) -- 01/30/17 -- PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration ("FDA") for its PPP0 ...


30.01.2017

Tetra BioPharma Announces it Has Entered into a Clinical Research Partnership with Sante Cannabis, Quebec''s Leading Medical Cannabis Institution

OTTAWA, ONTARIO -- (Marketwired) -- 01/23/17 -- PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("TetraBio" or the "Company" or "TBP") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF) is pleased to announce that it has entered into a clinical research partnership with Sante Cannabis. Under the partnership, Sante Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial eviden ...


23.01.2017

Tetra BioPharma Announces it Has Entered into a Clinical Research Partnership with Sante Cannabis, Quebec''s Leading Medical Cannabis Institution

OTTAWA, ONTARIO -- (Marketwired) -- 01/23/17 -- PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("TetraBio" or the "Company" or "TBP") (CSE: TBP)(CSE: TBP.CN) is pleased to announce that it has entered into a clinical research partnership with Sante Cannabis. Under the partnership, Sante Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety ...


23.01.2017

Tetra Bio-Pharma Inc. Announces a New Appointment to its Scientific and Clinical Advisory Board

OTTAWA, ONTARIO -- (Marketwired) -- 01/11/17 -- PhytoPain Pharma Inc. ("PhytoPain Pharma" or "PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GRPOF), is pleased to announce the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development. The ...


11.01.2017

Tetra Bio-Pharma Inc. Enters Into Binding Letter of Intent for Co-Development and Commercialization of Health Care Products Containing Cannabinoids and Closes a Private Placement

OTTAWA, ONTARIO -- (Marketwired) -- 01/10/17 -- Tetra Bio-Pharma Inc. ("TetraBio", "TBP", or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PINK: GROPF) through its subsidiary, Agro-Tek Health Inc. ("GTK"), is pleased to announce that it has entered into a binding letter of intent to form a joint venture with Ford''s Family Pharmacy and Wellness Center ("FFP") in Moncton, New Brunswick. The primary objective of this venture is the develop ...


10.01.2017

Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials

OTTAWA, ONTARIO -- (Marketwired) -- 12/06/16 -- Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE: TBP)(CSE: TBP.CN) and (OTC PINK: GRPOF) is conducting a non-brokered private placement with Aphria Inc. (TSX VENTURE: APH)(OTCQB: APHQF) of 5,000,000 units at a price of $0.20 per unit for aggregate gross proceeds of $1,000,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common ...


06.12.2016

Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001

OTTAWA, ONTARIO -- (Marketwired) -- 11/23/16 -- PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP) (CSE: TBP.CN) (OTC PINK: GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.The Company confirmed that, on ...


23.11.2016

LTE and TETRA Integration Critical for Updating Legacy PMR Systems say ETELM

Technologies must come together and integrate now to tackle increasingly complex challenges within PMR, urges ETELM Director Cologne, Germany, 22 November 2016 – Nicolas Hauswald, Sales and Marketing Director of ETELM, a leading manufacturer of advanced Mission Critical communications systems, says LTE should offer additional broadband services but not replace TETRA. Instead, the two technologies should come together in a unified way, on the LTE Core as an open, international standard platform ...


22.11.2016

Tetra Bio-Pharma Achieves DTC Eligibility in the United States

OTTAWA, ONTARIO -- (Marketwired) -- 11/16/16 -- Tetra Bio-Pharma Inc. ("TetraBio" or the "Company") (CSE: TBP) (CSE: TBP.CN) (OTC PINK: GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible". This electronic method of clearing securit ...


16.11.2016

Tetra Bio-Pharma Inc. Announces the Closing of $914,456 Non-Brokered Private Placement

OTTAWA, ONTARIO -- (Marketwired) -- 11/04/16 -- Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE: TBP) is pleased to announce that it has closed a non-brokered private placement of 6,096,369 units at a price of $0.15 per unit for aggregate gross proceeds of $914,456. Each unit consists of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 per share for a period of twelve mont ...


04.11.2016

Tetra Bio-Pharma Enters Into Medical Cannabis Supply Agreement With ACMPR Licensed Producer Aphria Inc.

OTTAWA, ONTARIO -- (Marketwired) -- 11/03/16 -- Tetra Bio-Pharma Inc. ("TetraBio" or the "Company") (CSE: TBP) through its subsidiary, PhytoPain Pharma Inc. ("PPP"), is pleased to announce that it has signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations ("ACMPR") licensed producer Aphria Inc. ("Aphria") (TSX VENTURE: APH)(OTCQB: APHQF) for the supply of dried medical cannabis as an Active Pharmaceutical Ingredient ( ...


03.11.2016

Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board

OTTAWA, ONTARIO -- (Marketwired) -- 11/02/16 -- Tetra Bio-Pharma Inc. ("TetraBio" or the "Company") (CSE: TBP) through its subsidiary, PhytoPain Pharma Inc. ("PPP"), is pleased to announce that it held its Scientific and Clinical Advisory Board ("CAB") meeting on October 29th. The CAB reviewed the development program of PPP''s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescript ...


02.11.2016

Tetra Bio-Pharma Announces Acquisition of Intellectual Property for the Development of Natural Health Products Through Its Agro-Tek Subsidiary

OTTAWA, ONTARIO -- (Marketwired) -- 10/26/16 -- Tetra Bio-Pharma Inc. ("Tetra Bio" or the "Company") (CSE: TBP)(CSE: TBP.CN), through its subsidiary, Agro-Tek Inc. ("AGTK"), is pleased to announce that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa.The recently announced awarding of the N ...


26.10.2016

Tetra Bio-Pharma Inc. Is Increasing Its $750,000 Non-Brokered Private Placement to $1,000,000

OTTAWA, ONTARIO -- (Marketwired) -- 10/24/16 -- Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE: TBP)(CSE: TBP.UN) is increasing its $750,000 non-brokered private placement (ref.: news release of October 20, 2016) to $1,000,000 for up to 6,666,667 units at a price of $0.15 per unit. Each unit will be consisting of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a peri ...


24.10.2016

Tetra Bio-Pharma Inc. Announces a $750,000 Non-Brokered Private Placement & Granting of Options

OTTAWA, ONTARIO -- (Marketwired) -- 10/20/16 -- Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE: TBP)(CSE: TBP.CN) is conducting a non-brokered private placement of up to 5,000,000 units at a price of $0.15 per unit for aggregate gross proceeds of up to $750,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following ...


20.10.2016

Tetra Bio-Pharma Announces Awarding of NSERC Engage Grant Partnership to Grow Pros MMP and McGill University

OTTAWA, ONTARIO -- (Marketwired) -- 10/19/16 -- Grow Pros MMP Inc. (MMP), a subsidiary of Tetra Bio-Pharma Inc. ("TetraBio" or the "Company" or "TBP") (CSE: TBP) is pleased to announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.As part of MMP''s mission to diversify and offer new products to consumers, with the award of the NSER ...


19.10.2016

Tetra Bio-Pharma Secures 2M Dollar Equity Facility from New York Private Equity Firm

OTTAWA, ONTARIO -- (Marketwired) -- 10/07/16 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTCQB: GRP0F) is pleased to announce that, on October 5, 2016, the Company entered into a non-binding agreement for a draw-down equity facility of up to $2,000,0000. Each Offering will occur exclusively at the option of the Company, throughout the 18-month term of the agreement.The agreement provides for equity private placement offerings, to be conducted ...


07.10.2016

Tetra Bio-Pharma Inc. Announces Its Pre-IND Meeting with FDA was Granted

OTTAWA, ONTARIO -- (Marketwired) -- 10/04/16 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN), through its subsidiary, PhytoPain Pharma Inc. ("PPP"), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it received a PRE-IND Acknowledgement and Meeting Request Granted letter from the US FDA.According to Dr. G. Chamberla ...


04.10.2016

Tetra Bio-Pharma Inc. Announces that its Phase I Trial of Inhaled Marijuana in Healthy Volunteers Will Be Performed by Algorithme Pharma, an Altasciences Company

OTTAWA, ONTARIO -- (Marketwired) -- 09/29/16 -- Tetra Brio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN), through its wholly-owned subsidiary, PhytoPain Pharma Inc. ("PPP"), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions, has selected Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy huma ...


29.09.2016

Trelleborg Acquires Anderson Seal

FORT WAYNE, IN -- (Marketwired) -- 09/08/16 -- Trelleborg, a world leader in engineered polymer solutions, announces that through its business area Trelleborg Sealing Solutions has signed an agreement and finalized the acquisition of Anderson Seal LLC, a privately owned US-based seal distributor and value-added service partner.Linda Muroski, President of Marketing Americas, says: "Anderson Seal''s dynamic company culture and vision complements that of Trelleborg Sealing Solutions ...


08.09.2016

Tetra Tech''s 10 Top-Valued Projects Led by Corpus Christi LNG, Global Mining Plans, an Industrial Info News Alert

SUGAR LAND, TX -- (Marketwired) -- 07/28/16 -- Researched by Industrial Info Resources (Sugar Land, Texas) -- In the past few years, Tetra Tech Incorporated (NASDAQ: TTEK) (Pasadena, California) has become one of the fastest-growing engineering, procurement and construction (EPC) firms, acquiring Canadian, Australian and South American companies. Industrial Info''s project database is tracking $41.31 billion in active projects involving Tetra Tech in some capacity. About 70% of the to ...


28.07.2016

Trelleborg Unveils Unique Primary Flight Control Seal Test Bench at FIA2016

HAMPSHIRE, UNITED KINGDOM and FORT WAYNE, IN -- (Marketwired) -- 07/06/16 -- announces its new Primary Flight Control Seal Test Bench at (Farnborough International Airshow) being held in Hampshire, England, from July 11-17. Located in the HA Traub Technical Center in Fort Wayne, Indiana in the U.S., this test equipment can uniquely offer a rapid multi-million cycle testing capability, considerably shortening the proving time of flight control applications.The Flight Control Seal Test Bench wi ...


06.07.2016

Swift Fuels Again Recognized by FAA as Leader in Unleaded Aviation Gasoline

WEST LAFAYETTE, IN -- (Marketwired) -- 04/05/16 -- a global leader in the development of high-performance unleaded aviation gasoline, announced today that its Unleaded 102 Motor Octane aviation gasoline (Avgas) was one of two fuels approved by the FAA''s Piston Aviation Fuels Initiative (PAFI) to advance to the next Phase of testing. This approval recognizes Swift Fuels as a true leader in unleaded avgas.The FAA, in collaboration with industry leaders, established PAFI as a nationwid ...


05.04.2016

Estonia Implements ASC’s Recording Solution for ESTER Radio Network

Hoesbach/Germany, April 4, 2016 – ASC has implemented its communications recording solution, EVOIPneo, for the TETRA public safety network in Estonia. The network, known as ESTER, encompasses more than 100 base stations and is used by police and rescue officers, border guards and emergency response staff. SMIT (the Center of Information Technology and Development), needed a new communications recording solution when it upgraded from TETRA 5.5 to 6.0. TETRA is an important standard enabling ra ...


04.04.2016

TC Chemicals Brings In High Quality Titanium Solutions For Diverse Needs

FOR IMMEDIATE RELEASE China (September 20, 2014) - TC Chemicals is basically a chemical plant that has come into existences on November in the year 2004. The company is the predecessors of Anhui Tianchang Organic Chemical which was established in the year 1998. It is being just 10 years for the company to come into business, dedicated itself in titanate products. It is not much time for the company to come into existence, however from the very starting day till date it is serving the society w ...


20.09.2014

Taylor Capital Group Engages Michael Sansom and Harold Turley as Advisors

SALT LAKE CITY, UT -- (Marketwire) -- 08/06/12 -- , LLC, general partner and investment manager of the , LP, has formed an advisory board. It has named two advisors: Michael Sansom, principal, Sussex Group, and Harold Turley, owner and executive vice president, Tetra.Each quarter, the advisory board will review the fund's finances, asset allocations, and strategic direction with management. The advisors will act as a voice for the limited partners, provide third party guidance and enhance ...


06.08.2012

Tetra Pak Plans Production Capacity Expansion of Carton Packaging in Brazil, an Industrial Info News Alert

CORDOBA, ARGENTINA -- (Marketwire) -- 07/12/12 -- Researched by Industrial Info Resources Latin America (Cordoba, Argentina) -- (Sao Paulo, Brazil), a leader in the Brazilian market for , is planning an expansion of production capacity at the Ponta Grossa Packaging Mill (Paraná, Brazil) in 2013 and 2015. The total cost of the investment is $100 million.For details, view the entire article by subscribing to Industrial Info's Premium Industry News at , or browse other breaking industrial n ...


12.07.2012

tetra4D Launches 3D PDF Converter(TM) 3.4

SEATTLE, WA -- (Marketwire) -- 05/31/12 -- tetra4D™, the exclusive 3D technology partner for Adobe® Acrobat®, today announced the release of 3D PDF Converter™ Version 3.4 -- the exclusive 3D solution authorized by Adobe® to run as an Acrobat plug-in.As the only authorized 3D plug-in for Adobe Acrobat, 3D PDF Converter leverages the robust publishing features of Adobe Acrobat with the ubiquity of FREE Adobe® Reader® to enable enterprise-wide data exchange and collaboration in 3D."We are de ...


31.05.2012

Tetra Bio-Pharma to Benefit from Intellectual Properties Created within the Cannabis Health Research Chair from the University of New Brunswick

OTTAWA, ONTARIO -- (Marketwired) -- 08/31/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it will benefit from the intellectual property (IP) created within the cannabis health research Chair (The Chair) from the University of New Brunswick (UNB). The Corporation also provided a corporate update.As part of the 5-year commitment from Tetra and the New Brunswick Health Research Foundation (NBHRF) to The Chair, Tet ...


31.08.2017

Tetra Bio-Pharma Announces Stock Option Grant to CEO

OTTAWA, ONTARIO -- (Marketwired) -- 07/25/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company. All of the options are exercisable at a price of $0.80 per share. All of the options will vest immediately of the date of grant ...


25.07.2017

Tetra Bio-Pharma Strengthens its Board with the Appointment of Dr. Bill Cheliak

OTTAWA, ONTARIO -- (Marketwired) -- 05/30/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), today announced that it has appointed Dr. W.M. (Bill) Cheliak to the Board of Directors effective immediately.Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of experie ...


30.05.2017

Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma

OTTAWA, ONTARIO -- (Marketwired) -- 05/23/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on ...


23.05.2017

Tetra Bio-Pharma Announces the Opening of a New Brunswick Office for Manufacturing & Sales Activities

OTTAWA, ONTARIO -- (Marketwired) -- 04/12/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTCQB: GRPOF) announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities. New Brunswick is becoming the hub for the Canadian Cannabis industry.Tetra is preparing to commercialize several retail products later this year with expected revenues to be generated for the corporation in the fourth quarter. Tetra ...


12.04.2017



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 59


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.